# Availability, market share and price of quality assured artemisinin-based combination therapies in private drug outlets after over a decade of Copayment mechanism in Uganda. Moses Ocan<sup>1\*</sup>, Winnie Nambatya<sup>2</sup>, Caroline Otike<sup>3</sup>, Loyce Nakalembe<sup>4</sup>, Sam Nsobya<sup>5</sup>

6

#### 7 Author affiliations

- <sup>1</sup>Department of Pharmacology & Therapeutics, College of Health Sciences, Makerere University, P. O.
  Box 7072, Kampala.
- <sup>2</sup>Department of Clinical Pharmacy, College of Health Sciences, Makerere University, P. O. Box 7072,
   Kampala.
- <sup>12</sup> <sup>3</sup>Data Department, Joint Clinical Research Centre, Lubowa, P. O Box 10005, Kampala, Uganda
- 13 <sup>4</sup>Department of Pharmacology, Soroti University, P.O. Box 211, Soroti, Uganda
- <sup>5</sup>Department of Pathology, College of Health Sciences, Makerere University, P.O. Box 7072, Kampala,
   Uganda
- 16
- <sup>\*</sup>Corresponding author: Moses Ocan, E-mail: <u>ocanmoses@gmail.com</u>; Tel: +256712234364
- 18
- 19
- 20
- 21
- ...
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29

It is made available under a CC-BY 4.0 International license .

#### 30 Abstract

**Background:** Malaria remains one of the leading causes of morbidity, and mortality in Uganda. A large proportion of malaria symptomatic patients seek healthcare in the private sector. However, availability and affordability are major barriers to access to effective treatment. The private sector copayment mechanism in Uganda aims to increase availability and affordability of antimalarial agents. Our study assessed the availability, price, and market share of quality assured artemisinin-based combination therapies (QAACTs) in private drug outlets after over a decade of copayment mechanism in the private sector in Uganda.

38 Methods: This was a cross-sectional survey of anti-malarial agents in private drug outlets in high 39 (Tororo, and Apac districts) and low (Kabale and Mbarara districts) malaria transmission settings. 40 Following the World Health Organization Health Action International (WHO/HAI) criteria, an audit of the 41 antimalarial agents was done using a checklist to determine availability, price, and market share of

42 QAACTs. Data was entered in Epi-data and analyzed in STATA ver 14.0 at 95% confidence level.

**Results:** A total of twenty-eight (28) private drug outlets (pharmacies and drug shops) were included 43 44 in the survey. One in seven Artemisinin-based combination therapies (ACTs) in the drug outlets were quality assured (QAACTs). Artemether-lumefantrine (AL), 8.9% (11/124) and Artesunate-Amodiaquine 45 46 (AQ), 7.3% (9/124) were the only QAACTs present in the drug outlets at the time of the survey. The 47 majority, 86.1%% (124/144) of antimalarial agents present in stock in the drug outlets were artemisinin based. The most common, 38.9% (56/144) ACT in the drug outlets was Dihydroartemisinin-Piperaguine 48 49 (DHP). Most, 69.4% (100/144) of the antimalarial agents were in high malaria transmission settings. The cost of ACT antimalarial agents is high in the country, USD 1.4 (Artemether-Lumefantrine, AL), USD 2.4 50 51 (Dihydroartemisinin-Piperaguine, DP), the first line and second-line agents respectively for treatment of uncomplicated malaria in Uganda. There was a statistically significant difference between the dispensing 52 53 price of the 'Green leaf' ACTs and the recommended price (p<0.001).

**Conclusion:** Quality assured artemisinin-based combination therapies (QAACTs) are not common in private drug outlets in low and high malaria transmission settings. All the drug outlets had at least one ACT antimalarial agent present on the day of the survey. The dispensing price of QAACTs was significantly higher than the recommended markup price. There is need for awareness creation, surveillance, and monitoring of the implementation of Copayment mechanism in the country.

59

60 Key words: Quality assured artemisinin agents, non-artemisinin agents, malaria, cost, self-medication

- 61
- 62
- 63
- 64
- 65

It is made available under a CC-BY 4.0 International license .

#### 66 Introduction

67 The World Health Organization (WHO) reported an overall increase in malaria burden globally of up to two million cases in 2020-2021 with most of the increase occurring in the WHO Africa 68 region (1). Uganda is among the four countries including Nigeria. Democratic Republic of Congo 69 and Mozambigue that accounted for nearly half of all malaria cases globally in 2020-2021 (1). 70 71 Malaria thus remains a disease of public health concern in Uganda accounting for 30-50% of all 72 out-patient visits, and 15-20% of all hospital admissions (2). The healthcare system in Uganda like most other low-and middle-income countries (LMICs) is faced with multiple challenges 73 including inadequate human resource and limited funding (3). The unreliable supply coupled 74 with high costs of antimalarial agents in health facilities common in most LMICs potentially 75 affect malaria treatment (4, 5). In Uganda, this is likely to be worsened by the high burden of 76 77 malaria.

78 In most low-and middle-income countries (LMICs), over 60% of the population first seek 79 treatment in the private sector (6). A study by Ocan et al., (7) reported over half of population in northern Uganda accessing antimalarial agents over the counter in private drug outlets. The 80 sector thus plays an integral role in the fight against malaria (8). Patients seeking malaria 81 treatment in the private sector are however faced with multiple challenges including high cost, 82 unreliable supply, and substandard antimalarial agents (5, 9). In most malaria affected countries 83 price remains the leading contributor to limited access to antimalarial agents (5, 10). These 84 potentially affects access to appropriate malaria treatment which potentially predisposes 85 86 patients to adverse treatment outcomes including exacerbation of the current resistance to 87 first-line antimalarial agents.

One of the key factors influencing access to appropriate malaria treatment is pricing of antimalarial agents (5). The Affordable medicines facility for malaria (AMFm) is a financing mechanism incorporating three elements; price reductions through negotiations with manufacturers of quality-assured ACTs (QAACTs), a buyer subsidy to the participating manufacturers, and interventions to support AMFm implementation and promote appropriate antimalarial use (11). Affordable Medicines Facility-malaria (AMFm), funded by three donors (UNITAID, the UK government and the Bill & Melinda Gates Foundation) was renamed as the

It is made available under a CC-BY 4.0 International license .

private sector co-payment mechanism and integrated into the existing Global Fund grants (12). 95 The AMFm initiative is intended to improve availability, affordability, and access to quality 96 97 assured artemisinin-based combination therapies (QAACTs) in the private sector (13). Under the AMFm, public and private importers pay manufacturers a subsidized price between \$0.005 98 and \$ 0.22 per treatment course, representing 1-20% of the manufacturer price (14). The 99 balance is then paid to the manufacturer via the co-payment fund (14). Uganda was part of the 100 countries where the initiative was first piloted and subsequently implemented the Copayment 101 mechanism following the AMFm transition period in 2013 (13). 102

Negotiations with manufacturers under the AMFm led to reductions in manufacturer price for 103 104 sales to private-for-profit buyers of up to 29-78% depending on package size, bringing prices 105 down to around the levels paid by public purchasers (15). This helped improve availability, 106 affordability, and access to QAACTs in the AMFm pilot countries. In Uganda the AMFm was 107 replaced by Copayment mechanism following the end of the pilot period (13). The approved 108 quality assured ACTs in Uganda include Artemether/lumefantrine, Artesunate/Amodiaquine, 109 Dihydroartemisinin/piperaquine, and Artesunate/Pyronaridine (16, 17). Uganda is currently 110 implementing 70% subsidy for all package sizes of QAACTs (13). However, the impact of the 111 Copayment mechanism in the private sector remains unclear. Therefore, this study assessed 112 availability, price, and market share of quality assured artemisinin-based combination therapies 113 (QAACT) in the private drug outlets in low and high malaria transmission settings in Uganda 114 after over a decade of implementing Copayment mechanism.

### 115 Methods

#### 116 Study design and setting

This was a cross-sectional study conducted in low (Kabale and Mbarara districts) and high (Apac
and Tororo districts) malaria transmission settings. Data on antimalarial agents present in the
drug outlets on the day of the survey was collected.

It is made available under a CC-BY 4.0 International license .

#### 121 Sample size, drug outlet selection and sampling

122 In each district (Tororo, Apac, Mbarara and Kabale), a comprehensive list of the available private drug outlets was compiled using the National drug authority register of drug outlets. 123 Additionally, a census was taken to identify all the private drug outlets (pharmacies and drug 124 shops) in each district prior to data collection. All the drug outlets identified from the National 125 drug authority register and the census were then included in the survey. Private drug outlets in 126 this study are defined as for-profit licensed establishments that dispense medicines. Two 127 research assistants, a pharmacist (KJ) and nurse (RK) conducted the antimalarial drug audit in 128 129 the private drug outlets. Each of the research assistants separately visited different drug outlets in the study districts. At each drug outlet prior to data collection the research assistants 130 introduced themselves and explained the study and provided approval letters from the Ethics 131 committee, UNCST and local authorities. The research assistants obtained a written informed 132 consent from the pharmacists/dispensers in each pharmacy prior to data collection which was 133 done between 15<sup>th</sup> June 2021- 21<sup>st</sup> December 2021. In each study district, the research 134 assistants moved from one drug outlet to the next until all the identified private drug outlets 135 136 were covered.

137

#### 138 Data collection

The WHO/HAI methodology was used for collection of data on availability and price of 139 antimalarial agents. In each drug outlet, the dispenser/pharmacist was requested to show the 140 research assistants all the antimalarial agents available in stock on the day of the survey. 141 Additionally, a stock card and dispensing logs were also obtained and screened. An audit of the 142 143 antimalarial agents that were provided, stock cards and dispensing logs was then done using a 144 data collection checklist. The tool was pre-tested in drug outlets in Kampala city and validated. Data was collected for each identified anti-malarial agent in the drug outlet. The WHO list of 145 antimalarial agents was used in identification of antimalarial agents present in stock during the 146 day of the survey. Additionally, the Ministry of Health list of guality assured artemisinin-based 147 agents in the country was also used in identifying QAACTs in the drug outlets. Data was 148 149 collected on, drug outlet type, generic name, brand name, active ingredients and strengths,

It is made available under a CC-BY 4.0 International license .

formulation, quality assured ACT (having a green leaf logo), non-quality assured ACT (without a green leaf logo), manufacturer and country of manufacture, type of antimalarial (artemisinin or non-artemisinin based), location of drug outlet (transmission setting), and package size. The price of the antimalarial agents was collected from the dispensing logs and the dispenser/pharmacist.

During each data collection day, the lead researcher reviewed all the data collection forms and visited 20% of all the drug outlets for quality control checks. Any discrepancies in the data collection tool were rectified through discussion with the data collectors and consensus.

#### 158 Data management and analysis

159 In this study, ACT antimalarial agents were classified into two categories: i) quality assured ACTs (QAACTs) are ACTs that comply with the Global Fund's ACT chemical regulation and have a 160 green leaf logo printed on its label and ii) non-quality assured ACTs (non-QAACTs) which are 161 162 ACTs without the green leaf logo on their labels. The Quality-assured ACTs were further divided into two categories: i) quality-assured first-line ACT (Artemether/Lumefantrine) and ii) quality-163 164 assured alternative first-line ACT (Artesunate/Amodiaguine) as per the national malaria treatment guidelines (18). Antimalarial availability was measured as the proportion of outlets 165 with at least one anti-malarial agent present on the day of data collection (survey). Additionally, 166 in each private drug outlet the proportion of specific anti-malarial categories present in stock 167 during the day of the survey was also calculated. The prices of antimalarial agents in the drug 168 outlets were converted to US dollars using the average annual exchange rate by the Bank of 169 Uganda in 2021. The antimalarial price data at the time of data collection is reported in terms 170 171 of adult equivalent doses, defined as the amount needed to treat a 60 kg adult (19).

Data was entered in EpiData *version* 4.2.0.0 and exported to STATA *version* 14.0 for cleaning and analysis. Antimalarial agents were summarized using frequencies and proportions, prevalence of antimalarial agents was also determined using proportions. Distribution of antimalarial agents across malaria transmission settings and type of drug outlet was compared using fisher's exact test of independence at 95% level of significance. Price of antimalarial agents was summarized using median and interquartile range.

It is made available under a CC-BY 4.0 International license .

#### 178 **Results**

#### **Descriptive results**

180 A total of twenty-eight (28) drug outlets were included in the survey of which majority, 78.6% (22/28) were pharmacies. All the drug outlets in the study districts (Apac, Tororo, Mbarara and Kabale) had at 181 least one antimalarial agent present in stock during the day of the survey. Of the 28 drug outlets visited 182 183 in this study, majority 82.1% (23/28) had a minimum of 5 different kinds of antimalarial agents present on the day of the survey. Most, 69.4% (100/144) of the antimalarial agents were in high malaria 184 185 transmission settings. The majority, 86% (124/144) of the antimalarial agents were tablet formulations. 186 Twelve, 8.3% (12/144) of the artemisinin based antimalarial agents in the drug outlets were 187 monotherapies (Table 1).

188

#### 189 Antimalarial agents present in the drug outlets on the day of the

#### 190 **Survey.**

A total of 144 antimalarial agents were present in the drug outlets on the day of the survey of which majority, 86.1% (124/144) were artemisinin-based agents. Of the Artemisinin based combination therapies, 61.1% (88/144) were in high malaria transmission settings and 68.8% (99/144) were found in pharmacies. For non-artemisinin based antimalarial agents, 8.3% (12/144) were in high malaria transmission setting and 11.1% (16/144) were in pharmacies.

196 Of the artemisinin-based agents, majority 90.3% (112/124) were Artemisinin-based combination 197 therapies (ACTs). Artesunate was the most common artemisinin monotherapy, 8.9% (11/124). All the artemisinin monotherapies 9.7% (12/124) were injectables (Artemether and Artesunate). Over a third 198 199 35.4% (51/144) of the antimalarial agents were first-line ACTs (Artemether-lumefantrine, 29.2%: 42/144 200 and Artesunate-amodiaquine, 6.3%: 9/144). Most first-line ACTs, 26.4% (38/144), 25.7% (37/144) were 201 in high malaria transmission setting and pharmacies respectively. Of the ACTs 70.2% (87/124), 66.9% 202 (83/124) were present in pharmacies and high malaria transmission settings respectively. There was no 203 statistically significant difference in the presence of ACTs in pharmacies and drug shops (p=0.318). 204 However, there was a statistically significant difference in the distribution of ACTs based on setting 205 (p=0.03).

It is made available under a CC-BY 4.0 International license .

Four batches, 2.8% of the Artemisinin based antimalarial agents available in stock in the drug outlets had passed their expiry date. Of the expired agents, three were artemisinin-based while one was a nonartemisinin-based agent (Table 1).

#### 210 Availability of Quality Assured Artemisinin Combination therapies

#### 211 (QAACTs)

One in every seven Artemisinin-based combination therapies in the drug outlets were Quality Assured Artemisinin combination agents ('Green leaf ACTs'; QAACT). Most, 9.7% (12/124) of the QAACTs were in pharmacies. The QAACTs were common, 13.7% (17/124) in drug outlets in high malaria transmission settings. The QAACTs were significantly distributed in the pharmacies within the study settings (p=0.031). While there was no significant difference in the distribution of QAACTs by malaria transmission setting (p=0.123). Artemether-lumefantrine (AL), 8.9% (11/124) and Artesunate-Amodiaquine (AQ), 7.3% (9/124) were the only QAACTs present in drug outlets on the day of the survey. All the Artesunate/Amodiaguine agents in drug outlets were 'Green leaf' ACTs (Table 1).

It is made available under a CC-BY 4.0 International license .

#### 244

## Table 1: Antimalarial agents (N=144) in drug outlets in high and low malaria transmission settings in Uganda

Antimalarial category	Description	Overall n (%)	Low malaria transmission n (%)	High malaria transmission n (%)	<i>p</i> -value
Artemisinin monotherapies	Artesunate	11 (7.6)	6 (4.1)	5 (3.5)	1.00
	Artemether	1 (0.7)	1 (0.7)	0	
Non-Artemisinin based monotherapies	Chloroquine	2 (1.4)	1 (0.7)	1 (0.7)	1.00
	Quinine	8 (5.6)	3 (2.1)	5 (3.5)	
	Mefloquine	1 (0.7)	0	1 (0.7)	
Artemisinin-based combination therapies (ACTs)	Artemether/lumefantrine	42 (29.1)	13 (9)	29 (20.1)	0.213
	Artesunate/Amodiaquine	9 (6.3)	0	9 (6.3)	
	Dihydroartemisinin/Piperaquine	56 (38.9)	15 (10.4)	41 (28.5)	
	Artesunate /Mefloquine	2 (1.4)	1 (0.7)	1 (0.7)	
	Artesunate/Pyronaridine	3 (2.1)	0	3 (2.1)	
Non-Artemisinin based combination therapies	Atovaquone/Proguanil	2 (1.4)	1 (0.7)	1 (0.7)	1.00
	Sulfadoxine/Pyrimethamine	7 (4.9)	3 (2.1)	4 (2.8)	
Quality Assured ACTs ('Green leaf ACTs	Artemether/lumefantrine	11 (7.6)	3 (2.1)	8 (5.5)	0.218
	Artesunate/Amodiaquine	9 (6.3)	0	9 (6.3)	
Expired antimalarial agents	Yes	4 (2.8)	1 (0.7)	3 (2.1)	1.00
	No	140 (97.2)	43 (29.9)	97 (67.3)	
Formulation	Powder	18 (12.5)	10 (6.9)	8 (5.5)	0.039
	Syrup	2 (1.4)	0	2 (1.4)	
	Tablets	124 (86.1)	34 (23.6)	90 (62.5)	

247 ACTs: Artemisinin-based Combination therapies; n=sample size; %: percentage

248

249

250

It is made available under a CC-BY 4.0 International license .

252

#### Price of antimalarial agents in drug outlets in Uganda 253

254

Arterolane maleate/piperaguine phosphate combination had highest median price among the 255 256 antimalarial combination agents, 4.9 USD. The median price for Artemether/lumefantrine (AL), 257 the first line agent for uncomplicated malaria in Uganda was 1.4 USD. 258 Dihydroartemisinin/Piperaquine (DP), the second-line agent for treatment of uncomplicate malaria in Uganda cost was sold at a median price of 1.7USD. Artesunate + Amodiaguine 259 260 (AS+AQ), the second-line alternative agent for uncomplicate treatment of uncomplicate malaria in Uganda the median price was 2.1 USD (Table 2). 261

262

#### 263 Table 2: Median price of oral antimalarial agents in drug outlets in Uganda

S/N	Generic name	Median price (USD)	IQR (USD)
1.	Artemether/Lumefantrine	1.4	0.9, 1.9
2.	Arterolane maleate/piperaquine Phosphate	4.9	2.4, 5.6
3.	Artesunate + Amodiaquine	0.8	0.7, 1.3
4.	Artesunate/Mefloquine	2.8	2, 4.2
5.	Chloroquine Phosphate	0.6	0.5, 0.8
6.	Dihydroartemisinin/Piperaquine	3.2	2.7, 4.2
7.	Mefloquine	1.1	0.7, 2.2
8.	Quinine sulphate	0.4	0.3, 0.4
9.	Sulfadoxine/Pyrimethamine	0.6	0.1, 0.4
10.	Atovaquone/Proguanil	1.9	1.8, 2.0
11.	Artesunate/Pyronaridine	2.2	0.1, 2.8
12.	Arterolane maleate/piperaquine Phosphate	4.9	2.4, 5.6

265

264

: US aollar, IQI nerquartie

- 268
- 269
- 270
- 271

# Price mark-ups on quality assured artemisinin-based combination therapies (QAACTs) in drug outlets in Uganda

The median dispensing price for adult dose of quality assured (QAACT: 'Green leaf') first-line ACT for uncomplicated malaria, artemether-lumefantrine (AL) (20/120mg) was USD 0.98, which is higher than the recommended retail price by 10.2%. The median dispensing price for quality assured Artesunate/Amodiaquine (AQ) (25/67.5mg) was USD 0.7 which is higher than the recommended retail price by 57%. There was a statistically significant difference between the dispensing price of the 'Green leaf' ACTs and the recommended retail price (p<0.001).

280

#### 281 **Discussion**

282 The study found at least one antimalarial agent present in all drug outlets during the day of the 283 survey. Additionally, Artemisinin-based combination therapies (ACTs) were the most common 284 antimalarial agents in the drug outlets. This is unlike the findings of a previous study by O'Connell et al., (20) done in six sub-Saharan African countries that reported a low prevalence 285 of ACTs in private sector. The implementation of Affordable medicines facility for malaria 286 (AMFm) program could have influenced the difference in the findings of the two studies. A 287 288 study by ACTwatch group et al., (13), reported an increase on availability of ACTs following 289 implementation of the AMFm-malaria program. The finding of our study is an indicator of wide 290 availability of Artemisinin-based combination therapies (ACTs), the current cornerstone for 291 malaria treatment in private drug outlets.

The immediate post AMFm pilot period was characterized by increases in the availability of QAACTs in the private sector in Uganda and all other countries where it was implemented (13, 14). However, our study found a low prevalence of QAACTs in private drug outlets after over a decade of implementing copayment mechanism following AMFm pilot period. This is like findings of a study by O'Connell et al., (20). The low availability of QAACTs in private drug outlets highlights the challenges of implementation of copayment mechanism especially lack of

It is made available under a CC-BY 4.0 International license .

supporting interventions like training of private sector healthcare personnel and behavioralchange communication (13, 14).

300

301 The study did not find oral artemisinin-based monotherapies in the drug outlets. The injectable 302 artemisinin monotherapies (Artesunate and Artemether) were however common. According to the National malaria case management guidelines, injectable artemisinin agents are indicated 303 304 in the treatment of severe malaria and are to be used alongside oral ACTs. The use of oral artemisinin monotherapies in malaria treatment was reported in Southeast Asia as one of the 305 drivers of artemisinin resistance development (21). Our findings are like those of a previous 306 study by ACTwatch et al., (13) and O'Connell et al., (20) who reported not finding artemisinin-307 308 based monotherapies in sub-Saharan Africa. The objectives of the AMFm were to make the 309 ACTs more available, accessible and to crowd out artemisinin monotherapies (13). The findings of our study could thus be due to the emphasis placed on the Artemisinin based combination 310 therapies through the AMFm and Copayment mechanism in the country. In addition, the 311 312 absence of artemisinin monotherapies in Uganda could be due to the World Health Organization (WHO) recommendation to malaria affected countries to ban importation and 313 manufacture of these agents. 314

315 The study found non-artemisinin antimalarial agents in the drug outlets across the country. This is like the findings of a study by O'Connell et al., (20) which reported high prevalence of non-316 317 artemisinin agents in sub-Saharan African countries. Our study found, chloroquine, guinine and 318 Sulphadoxine/Pyrimethamine (SP) as common non-artemisinin agents in drug outlets. Presence of non-artemisinin therapies in the private drug outlets could be due to their perceived 319 effectiveness and familiarity from previous use coupled with provider behavior and beliefs (7, 320 22). Sulphadoxine/Pyrimethamine (SP) is recommended for use in prophylaxis against malaria 321 in pregnancy (23). Additionally, Quinine is a second line agent in treatment of severe malaria in 322 the country (18). However, the use of chloroquine was discontinued in 2006 (24) due to 323 324 widespread resistance. The continued presence of chloroquine in private drug outlets is an 325 indicator of access and use by communities in management of symptoms of malaria. Recent

It is made available under a CC-BY 4.0 International license .

studies in Uganda have reported persistence of *P. falciparum* resistance against chloroquine over two decades after discontinuation of its use in the country (25). Therefore, continued use of chloroquine by communities is likely to lead to inadequate treatment and increased risk of unwanted malaria treatment outcomes.

330 Dihydroartemisinin/Piperaquine (DP) and Artemether/lumefantrine (AL), the two most popular ACTs had a high median dispensing price for a full adult dose ranging from USD 1.4 – 2.4. The 331 332 median price of the subsidized ACTs ('Green leaf ACTs') was also significantly higher than the 333 non-subsidized agents. This is similar to the prices reported in a study by O'Connell et al., (20) done in six malaria endemic countries in sub-Saharan Africa. A previous study by Tougher et al., 334 335 (14) also found no significant change in ACT prices following implementation of AMFm pilot 336 program in Uganda. In a country where majority of the rural communities live under USD 1.0 a day, the reported prices of ACTs are potentially prohibitive. The reported high cost of ACTs 337 338 potentially hinders access to appropriate and effective malaria treatment in the country. 339 Recent studies in Uganda have reported high over-the-counter access of antimalarial agents 340 which coupled with the high cost of ACTs could drive inappropriate use (7, 26). With the emerging artemisinin resistance, inappropriate use of ACTs is likely to exacerbate malaria 341 342 parasite resistance in the country (27). The high cost of quality assured ACTs in the private 343 sector despite government subsidy highlights the challenge of implementation of government 344 programs especially in LMICs. There is thus need for regular monitoring of the implementation 345 of copayment mechanism for improvement of availability and access to quality assured ACTs in the private sector. 346

The study had some limitations, the overt method used is likely to be affected by the pharmacists not reporting the actual practice in the pharmacy. However, the additional review of stock cards and drug dispensing logs in the pharmacies and drug shops helped collaborate the findings of the study.

351

It is made available under a CC-BY 4.0 International license .

#### 353 **Conclusion:**

The results of our study indicate low prevalence of QAACTs in private drug outlets after over a decade of implementation of copayment mechanism in Uganda. Prices of both QAACTs and non-QAACTs remain high in private drug outlets (pharmacies and drug shops) despite the subsidies on QAACTs. There is need for consistent implementation of Copayment supporting interventions to help create demand for QAACTs among private sector health providers and the population. The Ministry of Health needs to conduct a review of the copayment mechanism to establish barriers to its implementation in the country.

#### **361** Author contribution

Conceptualization of the study (MO and SN), data curation and formal analysis (CO), methodology and investigation (MO and LN), validation (WN), Writing-original draft preparation (MO), supervision (SN). All the authors reviewed and edited the final version of the manuscript.

#### 365 Acknowledgements

We acknowledge Mr. Tayebwa Mordecai and Ms. Joanita Birungi for managing and coordinating field data collection. We are grateful to the research assistants, Ms. Ruth Kokusiima, Ms. Kadesemba Phoenah, Mr. Olwortho Wilfred, and Mr. Kato Henry for the work done during the field data collection. All authors read and approved the final manuscript.

370

371

372

#### 373 **References**

World Health Organisation. World malaria report 2022. Geneva, Switzerland: WHO;
 2022.
 Ministry of Health. Malaria guarterly report. Kampala, Uganda: Ministry of Health; 2023.

Oleribe OO, Momoh J, Uzochukwu BS, Mbofana F, Adebiyi A, Barbera T, et al. Identifying
 Key Challenges Facing Healthcare Systems In Africa And Potential Solutions. Int J Gen Med.
 2019;12:395-403.

Oridanigo EM, Salgedo WB, Kebene FG. Affordability of essential medicines and
 associated factors in public health facilities of Jimma Zone, Southwest Ethiopia. Adv Pharmacol
 Pharm Sci. 2021;2021:1-9.

5. Palafox B, Patouillard E, Tougher S, Goodman C, Hanson K, Kleinschmidt I, et al. Prices and mark-ups on antimalarials: evidence from nationally representative studies in six malariaendemic countries. Health Policy Plan. 2016;31(2):148-60.

386 6. UBOS. Uganda national household survey 2016/17. Kampala, Uganda: Uganda Bureau of
 387 Statistics 2017.

Ocan M, Bwanga F, Bbosa GS, Bagenda D, Waako P, Ogwal-Okeng J, et al. Patterns and
 Predictors of Self-Medication in Northern Uganda. PloS One 2014;9(3):e92323.

B. Davis B, Ladner J, Sams K, Tekinturhan E, de Korte D, Saba J. Artemisinin-based
combination therapy availability and use in the private sector of five AMFm phase 1 countries.
Malar J. 2013;12:135.

Ocan M, Nakalembe L, Otike C, Omali D, Buzibye A, Nsobya S. Pharmacopeial quality of
 artemether-lumefantrine anti-malarial agents in Uganda. Malar J. 2023;22(1):165.

395 10. World Health Organisation. Medicines strategy 2008–2013. Geneva, Switzerland: WHO;
396 2008.

Adeyi O, Atun R. Universal access to malaria medicines: innovation in financing and
 delivery. Lancet. 2010;376(9755):1869-71.

Opiyo N, Yamey G, Garner P. Subsidising artemisinin-based combination therapy in
 the private retail sector. Cochrane Database of Systematic Reviews. 2016;3(3):CD009926.

401 13. ACTwatch Group, Tougher S, Hanson K, Goodman C. What happened to anti-malarial 402 markets after the Affordable Medicines Facility-malaria pilot? Trends in ACT availability, price 403 and market share from five African countries under continuation of the private sector co-404 payment mechanism. Malar J. 2017;16(1):173.

14. Tougher S, ACTwatch Group, Ye Y, Amuasi JH, Kourgueni IA, Thomson R, et al. Effect of the Affordable Medicines Facility--malaria (AMFm) on the availability, price, and market share of quality-assured artemisinin-based combination therapies in seven countries: a before-andafter analysis of outlet survey data. Lancet. 2012;380(9857):1916-26.

409 15. Roll Back Malaria. Updated ACT prices under the Affordable Medicines Facility-malaria 1
410 March 2011 fact sheet. Geneva, Switzerland: WHO; 2011.

411 16. HEPS-Uganda. Assessing Access to Co-Paid Artemisinin-Based Combination Therapies for
412 Malaria in Uganda. Kampala, Uganda: Coalition For Health Promotion and Social Development
413 (HEPS-Uganda); 2017.

414 17. Ministry of Health. The Uganda Malaria Reduction Strategic Plan (2014–2020):
415 accelerated nationwide scale up to achieve universal coverage of cost effective malaria
416 prevention and treatment interventions. Kampala, Uganda: Ministry of Health (MoH); 2014.

417 18. Ministry of Health. Uganda National Malaria Control Policy. Kampala, Uganda: National
418 Malaria Control Program, Ministry of Health; 2011.

419 19. Shewchuk T, O'Connell KA, Goodman C, Hanson K, Chapman S, Chavasse D. The
420 ACTwatch project: methods to describe anti-malarial markets in seven countries. Malar J.
421 2011;10:325.

422 20. O'Connell KA, Gatakaa H, Poyer S, Njogu J, Evance I, Munroe E, et al. Got ACTs?
423 Availability, price, market share and provider knowledge of anti-malarial medicines in public
424 and private sector outlets in six malaria-endemic countries. Malar J. 2011;10:326.

425 21. Dondorp AM, Yeung S, White L, Nguon C, Day NP, Socheat D, et al. Artemisinin 426 resistance: current status and scenarios for containment. Nat Rev Microbiol. 2010;8(4):272-80.

- 427 22. Masanja IM, Lutambi AM, Khatib RA. Do health workers' preferences influence their 428 practices? Assessment of providers' attitude and personal use of new treatment 429 recommendations for management of uncomplicated malaria, Tanzania. BMC Public Health. 430 2012;12:956.
- 431 23. World Health Organization. Guidelines for the treatment of malaria. 3rd ed. Geneva,432 Switzerland. : WHO; 2015.
- 433 24. Nanyunja M, Nabyonga Orem J, Kato F, Kaggwa M, Katureebe C, Saweka J. Malaria
  434 treatment policy change and implementation: the case of Uganda. Malar Res Treat.
  435 2011;2011:683167.
- 436 25. Asua V, Conrad MD, Aydemir O, Duvalsaint M, Legac J, Duarte E, et al. Changing
  437 Prevalence of Potential Mediators of Aminoquinoline, Antifolate, and Artemisinin Resistance
  438 Across Uganda. J Infect Dis. 2021;223(6):985-94.
- Sabot OJ, Mwita A, Cohen JM, Ipuge Y, Gordon M, Bishop D, et al. Piloting the global
  subsidy: the impact of subsidized artemisinin-based combination therapies distributed through
  private drug shops in rural Tanzania. PLoS One. 2009;4(9):e6857.
- Yasri S, Wiwanitkit V. Artemisinin resistance: an important emerging clinical problem in
  tropical medicine. Int J Physiol Pathophysiol Pharmacol. 2021;13(6):152-7.
- 444